487. Experience with Remdesivir for Treatment of SARS-CoV-2 in Patients with Liver Cirrhosis
Poster Abstracts
[키워드] acute respiratory syndrome
Admission
advanced liver disease
adverse event
Adverse reaction
Antiviral
approved
cause
caused
Child-Pugh score
Chronic Hepatitis B
chronic liver disease
cirrhosis
clinically
co-morbidities
collected
coronavirus
coronavirus disease
Course
COVID-19
COVID-19 guideline
demographics
discharge
discharged
Elevation
experience
expired
FDA
hospitalized patient
ICD-10
identify
In-hospital
in-hospital mortality
Laboratory
Liver cirrhosis
Liver disease
Mild
moderate
Mortality
NASH
National
nucleotide
offered
outcome
Patient
patients
patients who survived
Remdesivir
reported
requiring supplemental oxygen
Result
SARS CoV-2
SARS-CoV-2
serum
serum creatinine
steatohepatitis
therapy
Treatment
[DOI] 10.1093/ofid/ofab466.686 PMC 바로가기 [Article Type] Poster Abstracts
[DOI] 10.1093/ofid/ofab466.686 PMC 바로가기 [Article Type] Poster Abstracts